

CourtLink, Lexis/Nexis and Questel-Orbit Litigation Search for USP 6541021 Case: 10/719007




No Cases found in CourtLink Search.



Searched the Utility, Design and Plant Patents database.

LEXISNEXIS® Total Research System			Switch Cleant - Frein
Systems Search Research Facks 6xts FOCUS™ Terms period=6541021	Document Stephan Stephan Compress Resolts (1 - + 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1		
Wew. <u>KS95</u> (Foli <u>Quatern</u>	())))((1 of 1))))))	72777888	Print (Download)
	Save As Alert More Like Tota More Like Selected Text	*************	Line (Reference)
	Pat. No. 6541621 (Copy w. Cite)		
Source: Patent Law > Find Patents > Utility, Des Terms: patno=6541821 (Edit Search Success			
	522535 (09) 6541021 April 1, 2003		
	UNITED STATES PATENT AND TRADEMARK OFFICE GRANTED PATENT		
	8541021		
	Get Drawing Sheet 1 of 6		
	Access PDF of Official Patent *		
	Check for Patent Family Report PDF availability *		
	* Notes: A treassectional charge will be incurred for doubloading an Official Faconic of Patient Family Report. Four acceptance of this charge acceptance of this charge for doubloading is noteable of continued to be supported by the charge for doubloading is noteable of continued supported by the not included in any flat rate peckages.		
	Order Patent File History / Wrapper from REEDFAX(%		
	Link to Claims Section		
	April 1, 2003		
	Devices and methods for pain management		
INVENTOR: Johnson, Randolph Melius -	Half Moon Bay, California, United States (US): Theeuwes, Feix - Los Altos Hills, Californi	a, Unite	d States (US)
APPL-NO: 522535 (09)			
FILED-DATE: March 10, 2000			
GRANTED-DATE: April 1, 2003			
ASSIGNEE-PRE-ISSUE: June 27, 2000	- ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS)., DURECT CORF	PORATIO	ON 10240 BUBE
Lexis lists litigation at the	ne top of its patents: No litigation listed.		



Searched the Patent Cases from Federal Courts and Administrative Materials Database.

No Documents Found

No documents were found for your search terms

"6541021 or 6,541,021"

Click "Save this search as an Alert" to schedule your search to run in the future.

- OR -

Click "Edit Search" to return to the search form and modify your search.


Suggestions:

- Check for spelling errors.
- · Remove some search terms.
- Use more common search terms, such as those listed in "Suggested Words and Concepts"
- Use a less restrictive date range.

Save the search sean Alert

Edit Search

No documents found.



Searched the Patent, Trademark & Copyright Periodicals, Combined database.

No Documents Found

No documents were found for your search terms "6541021 or 6,541,021"

Click "Save this search as an Alert" to schedule your search to run in the future.

- OR -

Click "Edit Search" to return to the search form and modify your search.


Suggestions:

- · Check for spelling errors .
- · Remove some search terms.
- Use more common search terms, such as those listed in "Suggested Words and Concepts"
- Use a less restrictive date range.

Save this Selection as an Abert

Edit Search

No documents found.



Searched Lexis/Nexis News, All (English, Full Text) database.

0 articles found.

No Documents Found

No documents were found for your search terms

"6541021 or 6,541,021"

Click "Save this search as an Alert" to schedule your search to run in the future.

- OR -

Click "Edit Search" to return to the search form and modify your search.

Suggestions:

- · Check for spelling errors .
- · Remove some search terms.
- Use more common search terms, such as those listed in "Suggested Words and Concepts"
- · Use a less restrictive date range.

Save this Search as an Alert

Edit Search

Searched the Questel-Orbit, PlusPat database. Results are below.

```
PLUSPAT - ©Questel - image
1 / 1
Patent Number :
 US6541021 B1 20030401 [US6541021]
Title :
  (B1) Devices and methods for pain management
Patent Assignee :
  (B1) DURECT CORP (US)
Patent Assignee :
 Durect Corporation, Cupertino CA [US]
Inventor(s):
  (B1) JOHNSON RANDOLPH MELLUS (US); THEEUWES FELIX (US)
Application Nbr :
 US52253500 20000310 [2000US-0522535]
Priority Details :
 US52253500 20000310 [2000US-0522535]
 US12558999P 19990318 [1999US-P125589]
Intl Patent Class:
  (B1) A61F-002/00 A61F-013/00 A61K-009/22 A61K-009/24 A61N-043/42
IPC Advanced All:
 A61K-009/00 [2006-01 A - I R M EP]; A61K-009/22 [2006-01 A - I R M US];
 A61K-031/4468 [2006-01 A - I R M EP]; A61K-031/4535 [2006-01 A - I R M
 EP]; A61K-047/10 [2006-01 A - I R M EP]; A61K-047/14 [2006-01 A - I R M
 EP]; A61K-047/26 [2006-01 A - I R M EP]
IPC Core All:
 A61K-009/00 [2006 C - I R M EP]; A61K-009/22 [2006 C - I R M US];
 A61K-031/4468 [2006 C - I R M EP]; A61K-031/4523 [2006 C - I R M EP];
 A61K-047/10 [2006 C - I R M EP]; A61K-047/14 [2006 C - I R M EP];
 A61K-047/26 [2006 C - I R M EP]
EPO ECLA Class :
 A61K-009/00M5D
 A61K-031/4468
 A61K-031/4535
 A61K-047/10
 A61K-047/14
 A61K-047/26
 ORIGINAL (O): 424422000; CROSS-REFERENCE (X): 424423000 424424000
 424425000 424449000 424450000 424473000 424484000 514282000
 604890100 604891100 604892100
Document Type :
 Basic
Citations :
 US3141823 [US3141823]
 -US3760984 [US3760984]
  -US3845770 [US3845770]
  -US3916899 [US3916899]
  -US3923426 [US3923426]
  -US3987790 [US3987790]
  -US3995631 [US3995631]
  -US3998834 [US3998834]
 -US4016880 [US4016880]
 -US4036228 [US4036228]
 -US4111202 [US4111202]
 -US4111203 [US4111203]
 -US4167574 [US4167574]
 -US4203440 [US4203440]
 -US4203442 [US4203442]
 -US4210139 [US4210139]
 -US4327725 [US4327725]
 -US4360019 [US4360019]
  -US4487603 [US4487603]
  -US4576951 [US4576951]
```

```
-US4582835 [US4582835]
-US4588580 [US4588580]
-US4627850 [US4627850]
-US4681560 [US4681560]
-US4692147 [US4692147]
-US4725852 [US4725852]
-US4769372 [US4769372]
-US4781924 [US4781924]
-US4865845 [US4865845]
-US5057318 [US5057318]
-US5059423 [US5059423]
-US5112614 [US5112614]
-US5137727 [US5137727]
-US5180716 [US5180716]
-US5187177 [US5187177]
-US5234692 [US5234692]
-US5234693 [US5234693]
-US5346903 [US5346903]
-US5356635 [US5356635]
-US5451408 [US5451408]
-US5472943 [US5472943]
-US5486362 [US5486362]
-US5487739 [US5487739]
-US5512578 [US5512578]
-US5580876 [US5580876]
-US5589480 [US5589480]
-US5633000 [US5633000]
-US5660854 [US5660854]
-US5672167 [US5672167]
-US5728396 [US5728396]
-US5729396 [US5729396]
-US5747058 [US5747058]
-US5767125 [US5767125]
-US5798114 [US5798114]
-US5858388 [US5858388]
-US5866164 [US5866164]
-US5980927 [US5980927]
-US5985305 [US5985305]
-USRE36547 [USRE36547]
-US6096756 [US6096756]
-US6203813 [US6203813]
-US6245351 [US6245351]
-US6436091 [US6436091]
-EP9749391 [WO9749391]
-EP9851246 [WO9851246]
-WO9727840 [WO9727840]
-W09749391 [W09749391]
-WO9851246 [WO9851246]
-W09936071 [W09936071]
Paix et al., 1995, "Subcutaneous fentanyl and subfentanyl infusion
substitution for morph . . . ", vol. 3: 263-269.* - Anderson et al. (1998). "Alternate Routes of Opioid Administration in
Palliative Care: Pharmacologic and Clinical Concerns" J. Pharmaceutical
Care in Pain Symptom Control, vol. 6(1):5-21.
- Bansinath, et al. (1989). "Hyperglycemia does not modify the pupillary
effects of .mu. and .kappa. opiate agonists in mice" J. Ocular
Pharmacology, vol. 5(1): 33-43.
- Bruera et al. (1987), "Use of the subcutaneous route of the
administration of narcotics in patients with cancer pain" Cancer, vol.
62(2): 407-411.
- Cherny et al. (1995). "Opioid pharmacotherapy in the management of
cancer pain" Cancer, vol. 76(7): 1283-1293.
- Clotz et al. (1991). "Clinical uses of fentanyl, sufentanil, and
```

- alfentanil" Clinical Pharmacy, vol. 10: 581-593.
- Coda et al. (1997). "Comparative efficacy of patient-controlled administration of morphine, hydromorphone, or sufentanil for the treatment of oral mucositis pain following bone marrow transplantation" Pain, vol. 72: 333-346.
- Crane (1994). "Intermittent subcutaneous infusion of opioids in hospice home care: An effective, economical, manageable option" Am. J. Hospice & Palliative Care, vol. Jan./Feb. 8-12.
- Dhasmana et al. (1987). "Gastrointestinal transit following inthrathecal or subcutaneous narcotic analgesics" Arch. Int. Pharmacodyn., vol. 286: 152-161.
- Fuginaga et al. (1988). "Reproductive and teratogenic effects of sufentanil and alfentanil in Sprague-Dawley rate" Anesth Analg. vol. 67: 166-169.
- Geller et al. (1993). "A randomized double-blind comparison of epidural sufentanil versus intravenous sufentanil or epidural fentanyl analgesia after major abdominal surgery" Anest. Analg, vol. 76: 1243-1250.
- Kerr et al. (1988). "Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients" Annals of Internal Medicine, vol. 108;554-557.
- Leelanuntakit (1996). "Management of cancer-related pain with transdermal fentnyl" J. Med. Assoc. Thai, vol. 79(6): 341-346.
- Moulin et al. (1992). "Subcutaneous narcotic infusions for cancer pain: treatment outcome and guidelines for use" Can. Med. Assoc. J., vol. 146(6): 891-897.
- Mucha et al. (1990). "Parker and Radow test of drug withdrawal aversion: Opposite effect in rats chronically infused with sufentanil or amphetamine" Pharmacology Biochem. & Behavior, vol. 35: 219-224.
- Paix et al. (1995). "Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management" Pain, vol. 3:263-269.
- Satterlee (1991). "Criteria for use of fentanyl citrate, sufentanil citrate, and alfentanil hydrochlorid.sup.a " Clinical Pharmacy, vol. 10:635-637.
- Sj.o slashed.gren et al. (1994). "Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists" Pain, vol. 59:313-316.
- Taverne et al. (1992). "Comparative absorption and distribution pharmacokinetics of intravenous and epidural sufentanil for major abdomincal surgery" Clin. Pharmacokinet., vol. 23(3): 231-237.
- Van den Hoogen et al. (1987). "Epidural and subcutaneous morphine, meperidine (pethidine), fentany and sufentanil in the rat: Analgesia and other in vivo pharmacologic effects" Anesthesiology, vol. 66: 186-194.
- Van den Hoogen et al. (1988). "Respiratory effects of epidural and subcutaneous morphine, meperidine (pethidine), fentanyl and sufentanil in the rat" Anest Analq, vol. 67: 1071-1078.
- Wagner et al. (1997). "Pharmacokinetics and pharmacodynamics of sedatives and analgescics in the treatment of agitated critically ill patients" Clin. Pharmacokinet, vol. 33(6):426-453.
- Willens et al. (1993). "Pharmacodynamics, pharmacokinetics, and clinical uses of fentanyl, sufentanil, and alfentanil" Heart & Lung, vol. 22(3):239-251.
- Zeiler et al. (1991). "Kontinuierliche peridurale sufentanil-applikation zur postoperativen analgesie" Anaesthesist, vol. 40:543-548.
- Ahmedzai (1997), "New approaches to pain control in patients with cancer." Eur. J. Cancer, 33(6):S8-S14.
- Anderson et al. (1998), "Alternate routes of opioid administration in palliative care: pharmacologic and clinical concerns." J. Pharmaceut. Care Pain Sympt. Control. 6:5-21.
- Coyle et al. (1994). "Subcutaneous opioid infusions at home." Oncology, 8:21-27.

```
- Fine (1997), "Fentanyl in the treatment of cancer pain." Sem. Oncol.,
 24(16):S16-S27.
  - Finley (1990), "Pain management with spinally administered opioids."
 Am. J. Hosp. Pharm., 47(1):S14-S17.
  - Jeal et al. (1997). "Transdermal fentanyl. A review of its
 pharmacologic properties and therapeutic efficacy in pain control."
 Drugs, 53:109-138.
  - Kerr et al. (1988). "Continuous narcotic infusion with
 patient-controlled analgesia for chronic cancer pain in outpatients."
 Ann. Intern. Med., 108:554-557.
  - Kingery (1997), "A critical review of controlled clinical trials for
 peripheral neuropathic pain and complex regional pain syndromes." Pain,
  73:123-139.
  - Martin et al. (1983), "Epidural and intrathecal narcotics." Can.
 Anaesth. Soc. J., 30:662-673.
  - Shaw (1993), "Treatment of intractable cancer pain by electronically
 controlled parenteral infusion of analgesic drugs." Cancer,
 72:3416-3425.
 - Skaer (1993), "Management of pain in the cancer patient." Clin. Ther.,
 15:638-649.
 - Slattery et al. (1985), "Newer methods of delivery of opiates for
 relief of pain." Drugs, 30:539-551.
  - Vertafridda et al. (1987), "Intraspinal morphine for cancer pain."
 Acta Anaesthesiol Scand., 31(85):47-53.
Publication Stage:
  (B1) U.S. Patent (no pre-grant pub.) after Jan. 2, 2001
Abstract :
 The invention features devices and methods for the systemic delivery of
 fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the
 present invention, a drug formulation comprising fentanyl or a fentanyl
 congener is stored within a drug delivery device (e.g., contained in a
 reservoir or impregnated within a matrix within the controlled drug
 delivery device). The drug formulation comprises an amount of drug
 sufficient for treatment and is stable at body temperatures (i.e., no
 unacceptable degradation) for the entire pre-selected treatment period.
 The drug delivery devices store the drug formulation safely (e.g.,
 without dose dumping), provide sufficient protection from bodily
 processes to prevent unacceptable degradation of the formulation, and
 release the drug formulation in a controlled fashion at a
 therapeutically effective rate to treat pain. In use, the drug delivery
 device is implanted in the subject's body at an implantation site, and
 the drug formulation is released from the drug delivery device to a
 delivery site. The delivery site may be the same as, near, or distant
 from the implantation site. Once released at the delivery site, the drug
 formulation enters the systemic circulation and is transported to the
 site of action in the body to modulate the pain response (e.g., the
 brain or other pain sensory location).
Update Code :
 2003-15
1 / 1
      LGST - ©EPO
Patent Number:
 US6541021 B1 20030401 [US6541021]
Application Number :
 US52253500 20000310 [2000US-0522535]
Action Taken:
 20000627 US/AS-A
 ASSIGNMENT
 OWNER: DURECT CORPORATION 10240 BUBB ROAD CUPERTINO CALIF; EFFECTIVE
 DATE: 20000606
 ASSIGNMENT OF ASSIGNORS INTEREST; ASSIGNORS: JOHNSON, RANDOLPH
```

MELLUS;THEEUWES, FELIX;REEL/FRAME:010943/0101
Update Code :
 2004-29